肠道菌群促进肝癌发生的机制及其临床应用

肝脏 ›› 2021, Vol. 26 ›› Issue (6): 696-700.

肠道菌群促进肝癌发生的机制及其临床应用

付豪爽, 赵爽, 谢青

200025 上海交通大学医学院附属瑞金医院感染科

收稿日期:2021-04-20 出版日期:2021-06-30 发布日期:2021-07-19
通讯作者: 谢青,Email:xieqingrjh@163.com
基金资助:
上海市临床重点专科(感染病学)(shslczdzk01103);国家自然科学基金(81770587,82070604);十三五“科技部重大专项”(2017ZX10203201-008, 2018ZX09201016-003-001, 2017ZX10202202-005-004)

Received:2021-04-20 Online:2021-06-30 Published:2021-07-19

摘要/Abstract

摘要： 肝细胞癌(Hepatocellular Carcinoma,HCC)是全球肿瘤死亡的第三大原因,大多发生于慢性肝病患者中。现有证据显示,微生物群在肿瘤发生与抗肿瘤免疫反应中发挥关键作用。本文就肠道菌群在小鼠模型和HCC患者中促进HCC发生和发展的机制的研究进展进行综述,包括生态失调、肠道屏障的破坏和细菌代谢物的作用。此外,本文还回顾了近年来肠道菌群作为HCC患者潜在诊断工具以及免疫治疗新靶点的最新进展。

关键词: 肝细胞癌, 肠道菌群, 肠道屏障, 免疫

付豪爽, 赵爽, 谢青. 肠道菌群促进肝癌发生的机制及其临床应用[J]. 肝脏, 2021, 26(6): 696-700.

参考文献

[1] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018, 15: 397-411.
[2] Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017, 14: 527-539.
[3] Bellot P, García-Pagán JC, Francés R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology, 2010, 52: 2044-2052.
[4] Pasolli E, Truong DT, Malik F, et al. Machine Learning Meta-analysis of Large Metagenomic Datasets: Tools and Biological Insights. PLoS Comput Biol, 2016, 12: e1004977.
[5] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69: 107-120.
[6] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 2019, 68: 1014-1023.
[7] Gr?t M, Wronka KM, Krasnod?bski M, et al. Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis. Transplant Proc, 2016, 48: 1687-1691.
[8] Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature, 2014, 513: 59-64.
[9] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer cell, 2012, 21: 504-516.
[10] Yoshimoto S, Loo TM, Atarashi K, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 2013, 499: 97-101.
[11] G?bele E, Dostert K, Hofmann C, et al. DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol, 2011, 55: 1391-1399.
[12] Achiwa K, Ishigami M, Ishizu Y, et al. DSS colitis promotes tumorigenesis and fibrogenesis in a choline-deficient high-fat diet-induced NASH mouse model. Biochem Biophysical Res Commun, 2016, 470: 15-21.
[13] Chng KR, Chan SH, Ng AHQ, et al. Tissue Microbiome Profiling Identifies an Enrichment of Specific Enteric Bacteria in Opisthorchis viverrini Associated Cholangiocarcinoma. EBioMedicine, 2016, 8: 195-202.
[14] Ma C, Han M, Heinrich B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science, 2018, 360:eaan5931.
[15] Sethi V, Kurtom S, Tarique M, et al. Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response. Gastroenterology, 2018, 155: 33-37.e36.
[16] Yu LX, Yan HX, Liu Q, et al. Endotoxin accumulation prevents carcinogen-induced apoptosis and promotes liver tumorigenesis in rodents. Hepatology, 2010, 52: 1322-1333.
[17] Loo TM, Kamachi F, Watanabe Y, et al. Gut Microbiota Promotes Obesity-Associated Liver Cancer through PGE(2)-Mediated Suppression of Antitumor Immunity. Cancer Discov, 2017, 7: 522-538.
[18] Yamada S, Takashina Y, Watanabe M, et al. Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice. Oncotarget, 2018, 9: 9925-9939.
[19] Singh V, Yeoh BS, Chassaing B, et al. Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer. Cell, 2018, 175: 679-694.e622.
[20] Oellgaard J, Winther SA, Hansen TS, et al. Trimethylamine N-oxide (TMAO) as a New Potential Therapeutic Target for Insulin Resistance and Cancer. Curr Pharm Des,2017, 23: 3699-3712.
[21] Ringelhan M, Pfister D, O'Connor T, et al. The immunology of hepatocellular carcinoma. Nature Immunol, 2018, 19: 222-232.
[22] Wolf MJ, Adili A, Piotrowitz K, et al. Metabolic activation of intrahepatic CD8⁺ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. Cancer cell, 2014, 26: 549-564.
[23] Gorjifard S, Goldszmid RS. Microbiota-myeloid cell crosstalk beyond the gut. J Leukoc Biol, 2016, 100: 865-879.
[24] Kim CH. Immune regulation by microbiome metabolites. Immunology, 2018, 154: 220-229.
[25] Chou HH, Chien WH, Wu LL, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota. Proc Nat Acad Sci U S A, 2015, 112: 2175-2180.
[26] Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science, 2018, 359: 91-97.
[27] Elinav E, Garrett WS, Trinchieri G, et al. The cancer microbiome. Nat Rev Cancer, 2019, 19: 371-376.